Fusion Pharmaceuticals (AstraZeneca)

Fusion Pharmaceuticals, based in Hamilton, Ontario, is the alpha-emitter company acquired by AstraZeneca for 2.4 billion dollars in 2024, and its FPI-2265, an actinium-225 PSMA-I&T agent, is in phase 3. Its pipeline also includes FPI-2068, an EGFR by c-MET bispecific radioconjugate, and the company holds actinium-225 supply agreements. Nuclide links it to the AlphaBreak trial of FPI-2265 and the AcTION trial of 225Ac-PSMA-617, to targeted alpha therapy, to the actinium-225 PSMA agents record and to the radiopharmaceutical roadmap. Whether actinium PSMA therapy can improve on lutetium PSMA therapy is the question AlphaBreak will answer. Actinium-225 PSMA agents have their own page.

Headquarters

Hamilton, ON, CA

Scorecard

All companies

#39of 90 companies, score 8

phase 3 +3
phase 1/2 +1
targets +2
modalities +2

0 approved, 1 in phase 3, 1 earlier, 1 targets, 0 registry studies. Formula on the about page.

Deals

Deal map

Date	Deal	Type	Upfront	Total	Source
2024-03-19	Fusion Pharmaceuticals (AstraZeneca) to AstraZeneca FPI-2265 (actinium-225 PSMA) and the Fusion targeted alpha therapy platform	Acquisition	$21.00 per share in cash, about $2.0bn	up to about $2.4bn including a $3.00 per share contingent value right	source

Type

radiopharma

Website

www.astrazeneca.com

Products

2top

Phase 3Targeted alpha therapy

Actinium-225 PSMA agents

Alpha-emitting PSMA drugs that produce responses even after Pluvicto fails, held back mainly by isotope supply.

Phase 1alpha therapy

Actinium-225 FPI-2068

An antibody engineered to grab onto two markers found together on some solid tumours, but not on healthy cells, carries a powerful short-range radioactive payload into the tumour to try to destroy it.